📣 Send us your press release
Site updates every 15 minutes
Health

Innovent Receives Positive CHMP Recommendation for Lung Cancer Drug Zybrivo

The European Medicines Agency’s advisory committee has recommended approval for Innovent’s Zybrivo as a first-line treatment for non-small cell lung cancer.

16 November 2026

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the authorization of Zybrivo (sintilimab) for the treatment of non-small cell lung cancer (NSCLC). If finalized by the European Commission, the drug will be indicated for use in combination with chemotherapy for patients with metastatic or advanced disease.

This recommendation marks a significant regulatory milestone for Innovent, representing its first foray into the European market. The company has previously focused its commercial efforts primarily on China, where sintilimab is already established for various oncology indications.

The adoption of Zybrivo in Europe would provide clinicians with an additional PD-1 inhibitor option. The decision follows a review of clinical trial data demonstrating efficacy in frontline settings, positioning the drug as a potential addition to standard chemotherapy protocols for eligible lung cancer patients.

Original source: prnewswire.com